Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

New prostate cancer drugs: few CV effects?

New prostate cancer drugs: few CV effects? Encouraging alternative approaches to orchiectomy and estrogen therapy for advanced prostatic cancer were highlighted in a series of presentations at the recent XIIIth International Congress of Chemotherapy in Vienna. Among the most prevalent malignant neoplasms worldwide, prostate cancer may be difficult to treat because it has often metastasized to bone and other organs by the time of diagnosis. One new investigational approach involves the use of synthetic analogs of gonadotropin-releasing hormone (GnRH), while the other employs drugs designed to destroy prostatic tumor tissue selectively. Most of the synthetic GnRH agents now under study result from substitution of a different amino acid in the 6 position of the naturally occurring GnRH decapeptide. Unlike natural GnRH, which is released in pulsatile fashion from the hypothalamus and acts through the pituitary to ultimately stimulate testosterone production by the gonads, the synthetic agonists apparently occupy the pituitary GnRH receptors continuously, desensitizing them and thereby http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

New prostate cancer drugs: few CV effects?

Henahan, John
JAMA , Volume 250 (16) – Oct 28, 1983
Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/new-prostate-cancer-drugs-few-cv-effects-2O43dHqxJ8

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 1983 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1983.03340160005003
Publisher site
See Article on Publisher Site

Abstract

Encouraging alternative approaches to orchiectomy and estrogen therapy for advanced prostatic cancer were highlighted in a series of presentations at the recent XIIIth International Congress of Chemotherapy in Vienna. Among the most prevalent malignant neoplasms worldwide, prostate cancer may be difficult to treat because it has often metastasized to bone and other organs by the time of diagnosis. One new investigational approach involves the use of synthetic analogs of gonadotropin-releasing hormone (GnRH), while the other employs drugs designed to destroy prostatic tumor tissue selectively. Most of the synthetic GnRH agents now under study result from substitution of a different amino acid in the 6 position of the naturally occurring GnRH decapeptide. Unlike natural GnRH, which is released in pulsatile fashion from the hypothalamus and acts through the pituitary to ultimately stimulate testosterone production by the gonads, the synthetic agonists apparently occupy the pituitary GnRH receptors continuously, desensitizing them and thereby

Journal

JAMA – American Medical Association

Published: Oct 28, 1983

There are no references for this article.